binimetinib and Leukemia

binimetinib has been researched along with Leukemia* in 1 studies

Other Studies

1 other study(ies) available for binimetinib and Leukemia

Article	Year
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway. International journal of hematology, 2019, Volume: 110, Issue:2 Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G1 Phase; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Leukemia; MAP Kinase Signaling System; Morpholines; Mutation; Neoplasm Proteins; Oncogene Protein p21(ras); Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction	2019

Article

Year

Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.

International journal of hematology, 2019, Volume: 110, Issue:2

Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G1 Phase; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Leukemia; MAP Kinase Signaling System; Morpholines; Mutation; Neoplasm Proteins; Oncogene Protein p21(ras); Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction

2019